0001209191-22-008937.txt : 20220211
0001209191-22-008937.hdr.sgml : 20220211
20220211172633
ACCESSION NUMBER: 0001209191-22-008937
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220210
FILED AS OF DATE: 20220211
DATE AS OF CHANGE: 20220211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: King Andrew James
CENTRAL INDEX KEY: 0001823187
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 22622918
MAIL ADDRESS:
STREET 1: C/O CHINOOK THERAPEUTICS U.S., INC.
STREET 2: 1600 FAIRVIEW AVE. E.
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-485-7051
MAIL ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH, INC.
DATE OF NAME CHANGE: 20111107
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-10
0
0001435049
CHINOOK THERAPEUTICS, INC.
KDNY
0001823187
King Andrew James
C/O CHINOOK THERAPEUTICS, INC.
400 FAIRVIEW AVE. NO., 9TH FLOOR
SEATTLE
WA
98102
0
1
0
0
Chief Scientific Officer
Common Stock
2022-02-10
4
M
0
2500
0.35
A
6594
D
Common Stock
2022-02-10
4
S
0
2500
13.31
D
4094
D
Stock Option (right to buy)
0.35
2022-02-10
4
M
0
2500
0.00
D
2029-06-05
Common Stock
2500
68047
D
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
/s/ Kirk Schumacher, Attorney-in-Fact
2022-02-11